Evidence map›Paper›PMID 41532806›Full record

ArticleChemistry & biodiversity2026

1,2,4-Triazole-Acetamide Conjugates as hEGFR Inhibitors: Synthesis, Anticancer Evaluation, and In Silico Studies.

Bahadır Bülbül, Necla Kulabaş, Merve Gürboğa, Ozlem Bingöl Ozakpınar, Ümmühan Çakmak, Fulya Öz Tuncay, Yakup Kolcuoğlu, Mohit Agrawal, Mujeeb Khan, İlkay Küçükgüzel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bahadır BülbülDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Düzce University, Konuralp Campus, Düzce, Türkiye.
Necla KulabaşDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, İstanbul, Türkiye.
Merve GürboğaDepartment of Biochemistry, Faculty of Pharmacy, Marmara University, İstanbul, Türkiye.
Ozlem Bingöl OzakpınarDepartment of Biochemistry, Faculty of Pharmacy, Marmara University, İstanbul, Türkiye.
Ümmühan ÇakmakDepartment of Chemistry, Faculty of Science, Karadeniz Technical University, Trabzon, Türkiye.
Fulya Öz TuncayDepartment of Chemistry, Faculty of Science, Karadeniz Technical University, Trabzon, Türkiye.
Yakup KolcuoğluDepartment of Chemistry, Faculty of Science, Karadeniz Technical University, Trabzon, Türkiye.
Mohit AgrawalSchool of Medical & Allied Sciences, K. R. Mangalam University, Gurugram, India.
Mujeeb KhanDepartment of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, India.
İlkay KüçükgüzelDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Fenerbahçe University, İstanbul, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of novel 1,2,4-triazole-acetamide derivatives was synthesized and evaluated for anticancer and hEGFR inhibitory activity. The compounds were obtained via multistep synthesis and characterized by spectroscopic methods. Cytotoxicity was tested against PC-3, MCF-7, A549, and K562 cell lines. Compounds 18, 19, and especially 24 showed notable antiproliferative effects, with compound 24 exhibiting higher selectivity and potency than gefitinib. It also induced apoptosis and inhibited migration in A549 and PC-3 cells, while selectively promoting invasion in PC-3, suggesting EMT-related behavior. In vitro kinase assays revealed compound 20 as the most potent hEGFR inhibitor (IC

Indexed as

AcetamidesAntineoplastic AgentsErbB ReceptorsProtein Kinase InhibitorsTriazolesApoptosisCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureStructure-Activity Relationship1,2,4-triazoleacetamideAcetamidesAntineoplastic AgentsEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsTriazoles1,2,4‐triazolesapoptosiscancerhEGFR inhibitorsmolecular dynamics

Identifiers

PMID41532806
PMCPMC13419370

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.